{"entity":{"id":"tyra-biosciences","kind":"company","name":"Tyra Biosciences","aka":[],"tldr":"Tyra Biosciences designs precise pills against a family of growth-signal proteins called FGFRs, which are faulty in some bladder, liver and bile duct cancers and in a bone growth disorder.","summary":"Tyra Biosciences is a Carlsbad, California company developing next-generation FGFR inhibitors designed to avoid resistance mutations and to spare related kinases. Its lead candidate, dabogratinib (TYRA-300), is an FGFR3-selective inhibitor in clinical development for non-muscle invasive bladder cancer and low-grade upper tract urothelial cancer, and in the phase 2 BEACH301 study in achondroplasia. TYRA-430 (FGFR4/3) is in the phase 1 SURF431 study in advanced hepatocellular carcinoma and other solid tumours, and TYRA-200 (FGFR1/2/3) is in the phase 1 SURF201 study in intrahepatic cholangiocarcinoma and other FGFR2-altered tumours. Tyra completed its Nasdaq IPO in September 2021, raising 198.7 million US dollars gross.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://tyra.bio/"},{"label":"Pipeline","url":"https://tyra.bio/pipeline/"},{"label":"IPO closing 8-K (SEC)","url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312521276124/d220261d8k.htm"}],"tags":[],"related":[],"cancers":["urothelial","hcc","cholangiocarcinoma"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["fgfr2"],"drugs":["tyra-300"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06995677","nct05544552"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year and later financings not sourced. Investor news pages (ir.tyra.bio) returned 403."],"hq":"Carlsbad, CA","country":"US","companyType":"biotech","website":"https://tyra.bio/","ticker":"TYRA","stage":"public","investors":[],"funding":[{"round":"IPO","year":2021,"amountUsd":198700000,"source":"https://www.sec.gov/Archives/edgar/data/1863127/000119312521276124/d220261d8k.htm","note":"12.42 million shares at 16 US dollars including full exercise of the underwriters' option; closed 17 September 2021"}]},"route":"/companies/tyra-biosciences/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/"}],"drug":[{"id":"tyra-300","kind":"drug","name":"TYRA-300","route":"/drugs/tyra-300/"}],"trial":[{"id":"nct06995677","kind":"trial","name":"Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer","route":"/trials/nct06995677/"},{"id":"nct05544552","kind":"trial","name":"Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations","route":"/trials/nct05544552/"}]}}